FGF21 and metabolic dysfunction-associated steatohepatitis: Preclinical studies investigating the long-acting FGF21 analogue, B1344, in non-human primates with non-alcoholic steatohepatitis (NASH) demonstrated reduction of steatosis, attenuation of inflammation and fibrosis, and reduced hepatocyte injury after 11 weeks of therapy [78].